-
July 19, 2024 Lupin’s Alliance Partner ForDoz Receives U.S. FDA Approval for Doxorubicin Hydrochloride Liposome Injection
-
July 18, 2024 Lupin and Huons Sign License and Supply Agreement for Commercialization of Cyclosporine Ophthalmic Nanoemulsionin Mexico
-
July 16, 2024 Lupin Receives Tentative Approval from U.S. FDA for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets
-
July 12, 2024 Lupin Receives Approval from U.S. FDA for Topiramate Extended-Release Capsules
-
July 12, 2024 Lupin Receives EIR from U.S. FDA for its Dabhasa Facility
-
July 9, 2024 Lupin Receives Tentative Approval from U.S. FDA for Empagliflozin, Linagliptin and Metformin Hydrochloride Extended-Release Tablets
-
June 27, 2024 Lupin Receives Tentative Approval from U.S. FDA for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
-
June 22, 2024 Lupin Receives EIR from U.S. FDA for its Somerset Manufacturing Facility
-
June 17, 2024 Lupin Appoints Abdelaziz Toumi as CEO of its API CDMO Subsidiary
In this section
Media Contacts
-
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications